Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, australia

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages

  Chen, Marcus Y ^a,b   Stevens, Kerrie ^c   Tideman, Robin ^a   Zaia, Angelo ^c   Tomita, Takehiro ^c   Fairley, Christopher K ^a,b   Lahra, Monica ^d,e   Whiley, David ^f,g   Hogg, Geoff ^c  

^a MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Antibiotics; Gonococcal; Neisseria gonorrhoeae; Pharynx; Resistance

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFALEXIN; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; PENICILLIN DERIVATIVE;

ANAL COMPLAINT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CASE REPORT; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GONOCOCCAL PHARYNGITIS; GONORRHEA; HUMAN; MALE; MALE HOMOSEXUAL; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; PHARYNGITIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM; REINFECTION; SEXUAL ABSTINENCE; SEXUAL BEHAVIOR; THROAT CULTURE;

EID: 84884938999     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt017     Document Type: Article

References (9)

1. WHO and CDC. Consultation on the Strategic Response to the Threat of Untreatable Neisseria gonorrhoeae and Emergence of Cephalosporin Resistance in Neisseria gonorrhoeae. Manila: WHO Regional Office for the Western Pacific, 2010.
2. Tapsall J and members of the National Neisseria Network of Australia. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, ed. Antimicrobial Susceptibility Testing: Methods and Practices with an Australian Perspective. Sydney: Australian Society for Microbiology, 2004; 175-88.
3. Australian Gonococcal Surveillance Programme annual report, 2010. Commun Dis Intell 2011; 35: 229-36. http://www.health.gov.au/ internet/main/publishing.nsf/content/cda-cdi3503-pdf-cnt.htm/$FILE/ cdi3503b.pdf (30 April 2012, date last accessed).
4. Unemo M, Golparian D, Nicholas R et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in Europe (France): novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemotherapy 2012; 56: 1273-80.
5. Unemo M, Golparian D, Syversen G et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15: pii 1/4 19721.
6. Tapsall J, Read P, Carmody C et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58: 683-7.
7. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011; 16: pii 1/4 19792.
8. Ohnishi M, Saika T, Hoshina S et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011; 17: 148-9.
9. Chisholm SA, Mouton JW, Lewis DA et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65: 2141-8.